Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (3892)	4/17/2000 10:34:00 AM
From: Joe	Read Replies (2) \| Respond to of 4140

This was posted by esmithidoc on Raging Bull. Thought the longs would be interested. Joe By: esmithidoc Reply To: None Monday, 17 Apr 2000 at 8:59 AM EDT Post # 48748 of 48754 Truth for those who are worried As an ophthalmologist, I believe that I have some special insight into the world of refractive surgery in general, and as a follower of SNRS, some special insight into LTK in particular. It seems that there are several arguments that bashers always use, and I would like to inject some reason into the arguments. 1. The procedure is temporary. While it is true that some regression takes place with LTK, as long as the regression is known and consistent, ophthalmologists will not be too bothered by this. Touch-ups or "enhancements" seem like they should be easy to do (like the original procedure) if necessary. Unlike hyperopic LASIK, patients will not have to have a flap remanipulated with the resulting risks of infection, flap wrinkling, epithelial ingrowth, etc. Regression definitely takes place with hyperopic LASIK, but it is not as easy to enhance as LTK if necessary. 2. Management has done a poor job My interactions with Russ and the rest of SNRS management has been nothing but positive. They have a great product and have done what it takes so far to get it to the public. Whether or not all of their actions have been great for stockholders I don't know, but they have developed a good relationship with ophthalmologists, and that will be what ultimately drives the stock price. 3. The market for low hyperopic corrections is too small This could not be farther from the truth. In my practice, the market for this procedure is huge. Patient acceptance for the concept of LTK has been unbelievably strong, even without satisfied customers running around (that is what drives my LASIK practice). Almost no one would have LASIK done without previous surgery patients out there, but my patients are actually eager to have LTK done as soon as it is available. Eliminating any cutting, rapid recovery and lack of down time from work removes most of the obstacles in my patients' minds. Relatively low cost (we plan to charge approx. 1200-1300/eye) is also obviously a big plus. I honestly plan to do more LTK in the 2nd half of 2000 than LASIK for the entire year. Sorry for the length of the post, but it's usually helpful to revisit the reasons we all invested in SNRS to start with during difficult times.